Cytek Biosciences (CTKB) Non-Current Assets (2020 - 2026)

Cytek Biosciences' Non-Current Assets history runs 7 years deep, the most recent figure standing at $69.8 million for Q1 2026.

• Quarterly Non-Current Assets fell 31.62% year-over-year to $69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $356.3 million (down 12.21% YoY) and the FY2025 annual result came in at $69.5 million, down 32.51% from the prior year.
• Non-Current Assets was $69.8 million for Q1 2026 at Cytek Biosciences, roughly flat from $69.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $110.5 million in Q2 2025 and bottomed at $46.8 million in Q1 2022.
• A 5-year average of $87.1 million and a median of $99.6 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets surged 282.48% — and 2025, when it sank 32.51%.
• Cytek Biosciences' Non-Current Assets stood at $65.5 million in 2022, then surged by 56.44% to $102.4 million in 2023, then advanced by 0.64% to $103.1 million in 2024, then sank by 32.51% to $69.5 million in 2025, then gained by 0.38% to $69.8 million in 2026.
• Business Quant data shows CTKB's Non-Current Assets at $69.8 million in Q1 2026, $69.5 million in Q4 2025, and $106.4 million in Q3 2025.